A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
NCT05036512
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
129
Enrollment
INDUSTRY
Sponsor class
Conditions
Sickle Cell Disease
Interventions
DRUG:
GBT021601
Sponsor
Pfizer